FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

21 letters match. Newest first.

  1. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  2. Boothwyn Pharmacy, LLC

    Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.

    High risk
  3. Supply Center USA

    Supply Center USA offered unapproved Similasan and Boiron eye drug products for sale online.

    High risk
  4. Oasis Medical, Inc.

    FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.

    High risk
  5. Scope Health Inc

    FDA says Scope Health sold unapproved OTC eye drugs online and misbranded several products.

    High risk
  6. Thea Pharma, Inc.

    FDA warns Thea Pharma that IVIZIA OTC lubricant eye drops are an unapproved and misbranded new drug.

    High risk
  7. AACE Pharmaceuticals, Inc.

    AACE Pharmaceuticals distributed adulterated Lubricant PM Ointment made by CMO Brassica with CGMP violations and failed supplier qualification.

    High risk
  8. OSRX, Inc.

    OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.

    High risk
  9. Aspen Pharmacare Holdings Limited

    FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.

    High risk
  10. Velocity Pharma LLC

    Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.

    High risk
  11. Optikem International Inc.

    FDA warns Optikem International after inspection found inadequate aseptic controls for sterile ophthalmic drugs, including contamination and validation failures.

    High risk
  12. EzriCare LLC

    EzriCare distributed non-sterile Artificial Tears made by a CMO with CGMP violations, linked to a Pseudomonas outbreak.

    High risk
  13. Southern Tier Home Infusion, Inc. dba Pharmacy Innovations

    FDA warned compounding pharmacy Pharmacy Innovations that its sterile drugs were made under insanitary conditions and without valid patient prescriptions.

    High risk
  14. DR Vitamins, LLC dba DR Vitamin Solutions

    FDA warned DR Vitamin Solutions that its eye drops are unapproved new drugs and misbranded.

    High risk
  15. CVS Health

    FDA told CVS Health its unapproved Pink Eye Relief Drops are an illegal new drug made by a manufacturer with serious quality violations.

    High risk
  16. TRP Company, Inc

    FDA warns TRP Company that its homeopathic eye drops and ointments are unapproved new drugs and may be adulterated.

    High risk
  17. Similasan AG

    Similasan AG's ophthalmic drugs are unapproved new drugs and violate CGMP (manufacturing quality rules), FDA says.

    High risk
  18. K.C. Pharmaceuticals Inc.

    FDA warned K.C. Pharmaceuticals after inspections found manufacturing rule violations in sterile ophthalmic drugs, including inadequate contamination controls and cleaning validation.

    High risk
  19. ImprimisRx NJ

    FDA found insanitary sterile compounding and subpotent timolol-latanoprost eye drops at ImprimisRx NJ.

    High risk
  20. Sterling Pharmaceutical Services, LLC

    Sterling Pharmaceutical Services, LLC made sterile ophthalmic drugs with manufacturing violations and marketed unapproved new drugs.

    High risk
  21. Imprimis Rx LLC

    FDA warns Imprimis Rx over false, misleading promotion of compounded eye drug Pred-Moxi-Brom.

    Low